Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell
Treating your peptides with this level of care ensures that the last dose of your study is just as potent as the first
Attend a diabetes education program to learn more about how to manage your diabetes with medications, diet, exercise, and regular medical exams
10.1007/s10658-007-9236-3 67 HassanW.HussainM.BashirS.ShahA
Nervous system disorders Uncommon: Headache Not known: Convulsions*, Dizziness Heart disease Not known: Palpitations Vascular pathologies Uncommon: Hypertension, Hypotension Respiratory, thoracic and mediastinal pathologies Not known: Dyspnea Gastrointestinal disorders Common: Vomiting, Nausea, Diarrhea, Abdominal pain Uncommon: Dysgeusia, Dyspepsia, Dry mouth Skin and subcutaneous tissue disorders Uncommon: Abnormal skin odor ** Not known: Itching, Skin rash Musculoskeletal and connective tissue disorders Uncommon: Muscle spasms Not known: Myasthenia***, Muscle tension Systemic disorders and conditions related to the administration site Uncommon: Chest pain, Feeling abnormal, Pyrexia, Injection site reaction**** Diagnostic tests Uncommon: Increased blood pressure Very rare: Increased INR*****